168 related articles for article (PubMed ID: 28434343)
1. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Lavatelli F; Nuvolone M; Ferraro G; Palladini G; Merlini G
Amyloid; 2017 Mar; 24(sup1):64-65. PubMed ID: 28434343
[No Abstract] [Full Text] [Related]
2. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
3. Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation.
Yabe M; Ozkaya N; de Jong D; Aypar U; Ritorto MS; Barbé E; Miedema IHC; Sen F; Chapman JR; Landau HJ; Dogan A
Am J Surg Pathol; 2021 Jul; 45(7):939-944. PubMed ID: 33739787
[TBL] [Abstract][Full Text] [Related]
4. The genomic landscape of plasma cells in systemic light chain amyloidosis.
Boyle EM; Ashby C; Wardell CP; Rowczenio D; Sachchithanantham S; Wang Y; Johnson SK; Bauer MA; Weinhold N; Kaiser MF; Johnson DC; Jones JR; Pawlyn C; Proszek P; Schinke C; Facon T; Dumontet C; Davies FE; Morgan GJ; Walker BA; Wechalekar AD
Blood; 2018 Dec; 132(26):2775-2777. PubMed ID: 30446495
[No Abstract] [Full Text] [Related]
5. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
6. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
[TBL] [Abstract][Full Text] [Related]
8. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.
Sher T; Fenton B; Akhtar A; Gertz MA
Blood; 2016 Oct; 128(15):1987-1989. PubMed ID: 27543437
[No Abstract] [Full Text] [Related]
9. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
Kaufman GP; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2015 Mar; 90(3):181-6. PubMed ID: 25388651
[TBL] [Abstract][Full Text] [Related]
12. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
15. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Perlini S; Merlini G
Amyloid; 2017 Mar; 24(sup1):54-55. PubMed ID: 28434293
[No Abstract] [Full Text] [Related]
16. Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.
Milani P; Schönland S; Palladini G; Kimmich C; Basset M; Russo F; Foli A; Perlini S; Bochtler T; Ho AD; Merlini G; Hegenbart U
Amyloid; 2017 Mar; 24(sup1):56-57. PubMed ID: 28434298
[No Abstract] [Full Text] [Related]
17. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.
Manwani R; Foard D; Mahmood S; Sachchithanantham S; Lane T; Quarta C; Youngstein T; Rezk T; Lachmann HJ; Gillmore JD; Fontana M; Whelan C; Hawkins PN; Wechalekar A
Haematologica; 2018 Apr; 103(4):e165-e168. PubMed ID: 29305414
[No Abstract] [Full Text] [Related]
18. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
[TBL] [Abstract][Full Text] [Related]
19. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
20. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]